E‐cadherin is a robust prognostic biomarker in colorectal cancer and low expression is associated with sensitivity to inhibitors of topoisomerase, aurora, and HSP90 in preclinical models

E‐cadherin is a robust prognostic biomarker in colorectal cancer and low expression is associated with sensitivity to inhibitors of topoisomerase, aurora, and HSP90 in preclinical models

Cell–cell and cell–matrix adhesion proteins that have been implicated in colorectal epithelial integrity and epithelial‐to‐mesenchymal transition could be robust prognostic and potential predictive biomarkers for standard and novel therapies. We analyzed in situ protein expression of E‐cadherin (ECA...

Full description

Bibliographic Details
Main Authors: Jarle Bruun, Peter W. Eide, Christian Holst Bergsland, Oscar Bruck, Aud Svindland, Mariliina Arjama, Katja Välimäki, Merete Bjørnslett, Marianne G. Guren, Olli Kallioniemi, Arild Nesbakken, Ragnhild A. Lothe, Teijo Pellinen
Format: Article
Language:English
Published: Wiley 2022-06-01
Series:Molecular Oncology
Subjects:
colorectal cancer
drug screening
E‐cadherin
multiplex immunohistochemistry
pharmacoproteomics
prognostic biomarker
Online Access:https://doi.org/10.1002/1878-0261.13159

Internet

https://doi.org/10.1002/1878-0261.13159

Similar Items